Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free ESLAW Stock Alerts

Estrella Immunopharma (ESLAW) Competitors

Estrella Immunopharma logo
$0.14 +0.03 (+24.21%)
As of 05/14/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ESLAW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy Estrella Immunopharma stock or one of its competitors? MarketBeat compares Estrella Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Estrella Immunopharma include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to 60 Degrees Pharmaceuticals?

Estrella Immunopharma (NASDAQ:ESLAW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat 60 Degrees Pharmaceuticals' score of 0.44 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
60 Degrees Pharmaceuticals Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.01MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

How does Estrella Immunopharma compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTSW) and Estrella Immunopharma (NASDAQ:ESLAW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Company Net Margins Return on Equity Return on Assets
Alpha Tau MedicalN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

In the previous week, Alpha Tau Medical had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Alpha Tau Medical and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Alpha Tau Medical's score of 0.19 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
Alpha Tau Medical Neutral
Estrella Immunopharma Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alpha Tau MedicalN/AN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

Summary

Alpha Tau Medical and Estrella Immunopharma tied by winning 1 of the 2 factors compared between the two stocks.

How does Estrella Immunopharma compare to Apollomics?

Estrella Immunopharma (NASDAQ:ESLAW) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Apollomics N/A N/A N/A

In the previous week, Estrella Immunopharma and Estrella Immunopharma both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.89 equaled Apollomics'average media sentiment score.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Apollomics Very Positive

Summary

Apollomics beats Estrella Immunopharma on 1 of the 1 factors compared between the two stocks.

How does Estrella Immunopharma compare to BioVie?

BioVie (NASDAQ:BIVIW) and Estrella Immunopharma (NASDAQ:ESLAW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Estrella ImmunopharmaN/AN/AN/AN/AN/A

In the previous week, BioVie and BioVie both had 1 articles in the media. Estrella Immunopharma's average media sentiment score of 1.89 beat BioVie's score of 1.87 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Very Positive
Estrella Immunopharma Very Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Estrella Immunopharma N/A N/A N/A

Summary

Estrella Immunopharma beats BioVie on 1 of the 1 factors compared between the two stocks.

How does Estrella Immunopharma compare to Cardio Diagnostics?

Estrella Immunopharma (NASDAQ:ESLAW) and Cardio Diagnostics (NASDAQ:CDIOW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A N/A
Cardio Diagnostics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/AN/AN/AN/A
Cardio Diagnostics$14.83KN/AN/AN/AN/A

In the previous week, Cardio Diagnostics had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Cardio Diagnostics and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat Cardio Diagnostics' score of 0.43 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Overall Sentiment
Estrella Immunopharma Very Positive
Cardio Diagnostics Neutral

Summary

Cardio Diagnostics beats Estrella Immunopharma on 2 of the 3 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLAW vs. The Competition

Export
MetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$459.70M$6.34B$12.37B
Dividend YieldN/A3.86%2.80%5.35%
P/E RatioN/A3.8120.6625.63
Price / SalesN/A7,720.83545.7376.59
Price / CashN/A13.1343.2656.33
Price / BookN/A84.219.946.97
Net IncomeN/A-$96.07M$3.55B$333.62M
7 Day Performance-0.93%1.11%1.70%1.09%
1 Month PerformanceN/A0.36%0.49%3.08%
1 Year PerformanceN/A68.88%39.38%35.68%

Estrella Immunopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLAW
Estrella Immunopharma
N/A$0.11
-3.0%		N/A+57.4%$0.00N/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/A$0.05
+0.2%		N/A-13.3%$0.00$1.01MN/A2
DRTSW
Alpha Tau Medical
N/A$1.31
+33.6%		N/A+778.9%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.02
-5.7%		N/A+37.8%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.29
-5.0%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ESLAW) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel